CANCER IMMUNOTHERAPY INDEX

The Loncar Cancer Immunotherapy Index seeks to track the combined performance of a basket of companies that develop therapies to treat cancer by harnessing the body's own immune system. Immunotherapy is a transformational field within the biotechnology space that is expected to become a foundational treatment for cancer over the next ten years.  The index will provide a metric to follow its progress as researchers advance new technologies for the benefit of courageous patients who fight the disease.  It is an equal-weighted index containing both large pharmaceutical and growth-oriented biotechnology companies that are leading in this approach.

Screenshot 2022-11-25 at 1.00.33 PM.png
Screenshot 2022-11-25 at 5.47.45 PM.png
Screenshot 2022-11-25 at 5.48.32 PM.png

Chart

Index Constituents

Click on a name to learn more about its immunotherapy program

Screenshot 2022-11-25 at 1.01.20 PM.png

Prices delayed up to 15 min

regeneron-regn-logo.png
logo-49.png
image2-2.jpg
rHqnvszj_400x400.png
KR6D6PeA.jpeg
nuWloqwg.jpeg
yPcL9Gyw.png
IMAB-Logo.png
Genmab.jpg
InstilBio.png
ImmunityBio.png
712_main.jpg
Immunocore.jpg
iTeos.jpg
Lyell_Logo.jpg
BioNTech-300x195.png
ngm-logo-primary-1c-safety.png
nkarta-therapeutics_.png
celularity-horizontal-fullcolor-1.png
Arcellx_Primary_RGB_M01_V01__002_Logo.jpg
IGM_logo.jpg

Loncar Investments, LLC : P.O Box 15072, Lenexa, KS  66285 : 913-871-5007 : Not investment advice or a solicitation to buy or sell securities